We never forget that rare diseases alter entire lives—and we’re committed to changing that.
Rare changes everything
At The Center for Rare Diseases, we never forget that rare alters entire lives. We’re committed to changing that.
We dedicate our time, so they don't have to
The time and effort spent by the patient and their loved ones in merely researching and managing a rare disease is time better spent on living a fuller life. We dedicate our time to rare disease research so that one day, they won’t have to.
Every day can be delayed, postponed, or canceled when you or a loved one has a rare disease. We understand the unique challenges rare disease patients and trials face compared to those in more common indications. Lives are uprooted and postponed in search of treatment, and not just the lives of patients, but their entire care circles.
Our experience allows us to efficiently conduct rare disease studies by actively anticipating and proactively mitigating risks while maintaining focus on the patient and their quality of life. We understand that every day without treatment means another day filled with doctor’s appointments, lab work, postponed opportunities, and canceled plans.
The time and effort spent by the patient and their loved ones in merely researching and managing a rare disease is time better spent on living a fuller life. We dedicate our time to rare disease research so that one day, they won’t have to.Check out what we’re doing to fight rare disease.
The future of patient-focused clinical development is already happening.
We understand the challenges and critical success factors necessary to execute rare disease studies, and we have the experience to back it up. Our team has built mutually beneficial relationships with patients and patient advocacy groups to ensure your study has the best chance of success. We work with you to make sure you have a study with enrollment, compliance, and post-market potential, built off real patient insights and data. Because—when we all come together—we can make clinical development a care option and bring life-saving treatment options to patients and their families.Read how we’re accelerating rare disease clinical development.
Leveraging advanced analytics to enhance patient recruitment.
Our medical informatics allow us to qualify and quantify rare disease patients and treating physicians through public and private data sources. We use industry-leading third-party data sources, as well as claims, pharmacy, specialty lab, and diagnostic data and electronic health records. We also examine the competitive landscape and investigator performance. This evidence-based methodology, combined with our core set of study-branded tools, helps sites identify potential patients and educate them about the study and its requirements.
“With the right technology, we can reach patients where they are and, ultimately, speed the development of life-changing drugs for rare indications.”
Scott Schliebner, Senior Vice President, Scientific AffairsLearn how technology is reshaping the rare diseases landscape.
Reducing the patient burden of participation.
We incorporate the patient perspective into all we do, because our work is first and foremost for the patient. We’ve built partnerships with relevant patient advocacy groups to create stronger study awareness and support, and we practice social listening and conduct patient-focused feasibility and focus groups to better understand what patients want. Our recruitment and retention strategies include the voice of patients and their caregivers during study design and throughout the life of the study to ensure optimal performance.Watch how we’re engaging patients throughout our studies.
We are rare together.
When you come to PRA with a rare disease study, you can expect to work with us. We believe clinical research happens at the person-to-person level. That’s why we want you to know who we are, so you can trust in our partnership.Rare changes everything. Let’s change that, together.
The Future of Clinical Trials: Connected and Virtual Approaches for Rare Diseases
Scott Schliebner, Senior Vice President, Center for Rare Diseases at PRA Health Sciences talks about how amore patient-centred approach is needed to…
We’ve supported more than 150 infectious disease studies, leading to the approval of 13 important marketed products.
Certain challenges within the drug development landscape merit a dedicatedtask force of experts and capabilities. That’s why we built our collection…